ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1796

Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
Abstract Number: 1797

Factors Driving Opioid Use in United States Veterans with Gout
Abstract Number: 1798

Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Abstract Number: 1799

Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
Abstract Number: 1800

Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
Abstract Number: 1801

High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
Abstract Number: 1802

The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
Abstract Number: 1803

Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Abstract Number: 1804

Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies
Abstract Number: 1805

Effect of Short-Term Fruit Juice and Sugared Beverage Intake on Risk of Recurrent Gout Flares
Abstract Number: 1806

Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
Abstract Number: 1807

Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography (DECT) Analysis
Abstract Number: 1808

Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout
Abstract Number: 1809

Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
Abstract Number: 1810

Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].